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asthma questionnaires, instruments developed in accordance with
present regulatory expectations are lacking. To address this gap, the
Patient-Reported Outcome (PRO) Consortium’s Asthma Working
Group has developed a patient-reported asthma daily symptom diary
(ADSD) for use in clinical research to assess outcomes and support
medical product labeling claims in adults and adolescents with
asthma. Objectives: To summarize the qualitative research con-
ducted to inform the initial development of the ADSD and to provide
evidence for content validity of the instrument in accordance with the
Food and Drug Administration’s PRO Guidance. Methods: Research
informing the initial development and conﬁrming the content validity
of the ADSD is summarized. This comprised a review of published
qualitative research, semi-structured concept elicitation interviews (n
¼ 55), and cognitive interviews (n ¼ 65) with a diverse and represen-
tative sample of adults and adolescents with a clinician-conﬁrmed
diagnosis of asthma in the United States to understand the asthma
symptom experience and to assess the relevance and understanding
of the newly developed ADSD. Results: From the qualitative literature
review and concept elicitation interviews, eight core asthmaee front matter Copyright & 2016, International S
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ndence to: Adam Gater, Adelphi Values Ltd., Adelpsymptoms emerged. These were broadly categorized as breathing
symptoms (difﬁculty breathing, shortness of breath, and wheezing),
chest symptoms (chest tightness, chest pain, and pressure/weight on
chest), and cough symptoms (cough and the presence of mucus/
phlegm). Conceptual saturation was achieved and differences in the
experience of participants according to socio-demographic or clinical
characteristics were not observed. Subsequent testing of the ADSD
conﬁrmed participant relevance and understanding. Conclusions:
The ADSD is a new patient-reported asthma symptom diary devel-
oped in accordance with the Food and Drug Administration’s PRO
Guidance. Evidence to date supports the content validity of the
instrument. Item performance, reliability, and construct validity will
be assessed in future quantitative research.
Keywords: asthma, content validity, patient-reported outcomes,
symptoms.
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Asthma is a chronic inﬂammatory disorder of the airways that
causes recurrent episodes of coughing, wheezing, breathlessness,
and chest tightness [1]. These episodes are usually associated
with variable airﬂow obstruction that is often reversible, either
spontaneously or with treatment [2]. The worldwide prevalence
of asthma is estimated to be approximately 300 million, and it isexpected to increase by 33% to 400 million by 2025 [3]. Despite
advances in the understanding of asthma and broader availabil-
ity of disease management guidelines, the proportion of patients
with uncontrolled asthma remains high [4,5].
A number of objective methods for determining asthma
disease severity exist. Forced expiratory volume in 1 second
and peak expiratory ﬂow, for example, typically serve as standard
measurements of airway function in clinical studies. There is alsoociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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(including fractional exhaled nitric oxide, total Immunoglobin E, and
blood eosinophils) [6]. Among the goals of asthma management (as
highlighted in clinical guidelines), and an indicator of overall asthma
control, is the eradication of or reduction in asthma symptoms [7–9].
Nevertheless, there is a poor correlation between the aforemen-
tioned objective measures of disease severity and patients’ experi-
ence of asthma symptoms [10–12]. To provide a holistic
understanding of patient disease severity and asthma control in
clinical research, there is a need for standardized ways of assessing
patients’ experience of asthma symptoms.
Many symptoms of asthma can be known only to patients
themselves and are therefore best reported via patient-reported
outcome (PRO) instruments. Nevertheless, although there is no
shortage of PRO instruments used in asthma studies, no instrument
has been identiﬁed for the assessment of asthma symptoms that
has been developed according to the regulatory expectations
described by the US Food and Drug Administration (FDA) in its
guidance for industry titled “Patient-Reported Outcome Measures:
Use in Medical Product Development to Support Labeling Claims”
(PRO Guidance) [13]. Indeed, a recent asthma outcomes workshop by
the National Institutes of Health stated that “asthma clinical
research will highly beneﬁt from standardization of major outcomes
in terms of deﬁnition and assessment methodology” [14] and
concluded that no published asthma symptom diary had sufﬁcient
validation information to be chosen as a core asthma outcome for
use in clinical research sponsored by the National Institutes of
Health [15]. In particular, strong evidence supporting the content
validity (the extent to which the PRO measures the concept of
interest, i.e., asthma symptoms) of existing instruments in adoles-
cents and adults with asthma is lacking.
To ﬁll this gap, the PRO Consortium’s Asthma Working
Group (WG) at the Critical Path (C-Path) Institute [16] embarked on
the development and qualiﬁcation of the asthma daily symptom
diary (ADSD) in collaboration with the FDA. The intent is for the
ADSD to be used as a co-primary or secondary end-point in clinicalFig. 1 –Overview of studymethods. ADSD, asthma daily symptom di
tronic patient-reported outcome; FDA, Food and Drug Administrationtrials to establish treatment outcomes and to support medical
product labeling claims. This article summarizes the qualitative
research conducted to inform the initial development of the ADSD
and to provide evidence for content validity of the instrument in
accordance with the FDA PRO Guidance.Methods
Figure 1 summarizes the methods involved in the development
of the ADSD. At each stage of this process, input was obtained
from the Asthma WG, C-Path scientists, the expert panel (J.K.,
S.S., M.S., and J.H.), and representatives of the FDA Center for
Drug Evaluation and Research via the formal Drug Development
Tool qualiﬁcation process [17].
Qualitative interviews during the development of the ADSD
were conducted in accordance with the Declaration of Helsinki
and approval was obtained from the Copernicus Group Inde-
pendent Review Board (approval code ADE2-12-282).Review of Existing Qualitative Literature
A targeted review of published qualitative research studies was
conducted to identify the symptoms and effects experienced by
adults and adolescents with asthma. Published peer-reviewed
articles were identiﬁed via title and abstract searches in elec-
tronic bibliographic databases: MEDLINE, Embase, and PsycNFO.
Disease (i.e., asthma), symptom and impact (i.e., symptom,
control, health-related quality of life), and qualitative research
(i.e., qualitative, phenomenology, thematic analysis, grounded
theory, interview, focus group) medical subject headings (MeSH)
terms or keywords were combined using Boolean logic com-
mands. Searches were conducted in May 2012 and limited to
articles published in English, concerning human subjects and
published between 1997 and 2012.ary; C-Path, Critical Path; DDT, drug development tool; ePRO, elec-
; WG, Working Group. (Color version of ﬁgure available online).
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For articles to be considered for full review, abstracts were
required to reference asthma symptoms and/or impacts experi-
enced by adults and/or adolescents. Abstracts were also required
to reference qualitative research (e.g., patient interviews and
focus groups) or analytic methods (e.g., grounded theory and
thematic analysis). Articles were excluded if abstracts were not
related to the experience of asthma symptoms/impacts as
reported by the patient or an informant (e.g., parent). Abstracts
referring only to asthma in infancy were also excluded.
Articles selected for full-text review were evaluated and
salient information pertaining to study aim(s), sample demo-
graphic characteristics, methodology, and results were summar-
ized. From the extracted information, key concepts relating to
asthma symptoms and associated impact were identiﬁed and
used to inform the development of a preliminary conceptual
model outlining the experience of living with asthma as reported
by patients.
Concept Elicitation Interviews
Concept elicitation interviews were conducted to provide a
comprehensive understanding of the symptoms experienced by
adults and adolescents with asthma and how they talk about
these symptoms.
Recruitment
Forty-eight participants were targeted for inclusion in the inter-
views. This sample target was based on the projection that 12
interviews would be necessary to achieve conceptual saturation
[18,19] in each of the four pre-speciﬁed age groups: 12 to 14 years,
15 to 17 years, 18 to 45 years, and 46 years and older. Note that
(for adolescent participants in particular) exploration of the
experience of asthma symptoms in narrow age bands was
considered important to ensure the use of developmentally
appropriate language in the resulting instrument [20].
Participants were recruited via referrals from primary care
physicians/general practitioners or respiratory specialists from
ﬁve geographically diverse sites in the United States (Los Angeles,
New Orleans, Philadelphia/New Jersey, Pittsburgh, and St. Louis).
To be eligible for inclusion, participants were required to meet
the following inclusion/exclusion criteria:1. a physician diagnosis of asthma, in accordance with national
and international asthma guidelines (e.g., Expert Panel Report
3, Global Initiative for Asthma) [9,21] for at least 1 year;2. to have ﬁlled a prescription for asthma medication in the year
before recruitment and have experienced asthma symptoms
during the 3 weeks before the interviews;3. were non-smokers or had a cumulative history of less than
10-pack years;4. were older than 12 years and provided written consent (and
written parental assent received when relevant).
Participants were excluded from the study if they had1. a diagnosis of a respiratory condition other than asthma (not
including allergies or rhinitis);2. any other signiﬁcant lung, heart, gastrointestinal, or neuro-
logical disease;3. any other physical, learning, emotional, or cognitive difﬁcul-
ties limiting ability to actively participate in an interview;4. demonstrated a history of alcohol or drug abuse.
Recruitment quotas for the following characteristics were used to
ensure a diverse and representative sample of participants: age,sex, ethnicity, race, education, level of asthma control, history of
recent exacerbations, and medication use.
Interview procedure
All participants provided informed consent (or parental consent
and participant assent in the case of participants aged 12–17
years) before their participation in the study. Semi-structured
interviews (1 hour in duration) were conducted by trained
qualitative researchers. Initial discussions were broad and
open-ended to facilitate spontaneous elicitation of concepts.
Probes were used to gather information on speciﬁc topics of
interest (as informed by the qualitative literature review) only
once every opportunity for spontaneous elicitation had been
provided. Two creative exercises were also used to facilitate
spontaneous elicitation of concepts during the interview, by
having participants think about their condition from a different
perspective. Speciﬁcally, participants were asked to discuss both
a collage/picture (that they had created before the interview) and
to select an animal representing their experience of asthma (see
Appendix in Supplemental Materials found at http://dx.doi.org/
doi:10.1016/j.jval.2016.01.007). All interviews were digitally
recorded and transcribed verbatim.
Analysis
A qualitative analysis plan was developed a priori. A software
package (ATLAS.ti [Scientiﬁc Software Development GmbH, Berlin,
Germany]) was used to facilitate the storage, coding, and qual-
itative analysis of interview transcripts. To ensure that the con-
cepts elicited by participants had been fully explored during the
interviews, conceptual saturation was assessed. Conceptual satura-
tion is deﬁned as the point at which no new relevant or important
information emerges with the collection of more data [13]. Partic-
ipants were divided into three approximately equal groups on the
basis of the chronological order in which interviews were con-
ducted to allow the concepts elicited in each group to be compared
using a stepwise approach. Saturation was judged to be achieved if
no new concepts emerged in the ﬁnal group of interviews.
Analyses were conducted for the total sample and for subsamples
according to age, sex, ethnicity, race, education, level of asthma
control, history of recent exacerbations, and medication use.
Item Generation and Development of Draft Instrument
A 2-day item generation meeting was convened and attended by
members of the Asthma WG (including sponsor, C-Path, and
Adelphi Values representatives), the expert panel, and a linguistic
validation specialist. Findings from the concept elicitation inter-
views were presented and discussed to reach consensus regard-
ing key concepts for inclusion in an ADSD. During this meeting,
draft items, instructions, response options, and a hypothesized
conceptual framework were also developed. After the develop-
ment of the draft instrument, an independent electronic imple-
mentation assessment (to determine the feasibility of migrating
the instrument to electronic platforms) was conducted by repre-
sentatives from seven electronic PRO (ePRO) system providers
comprising the Instrument Migration Subcommittee of C-Path’s
ePRO Consortium. In addition, an in-depth translatability assess-
ment involving representatives from six different cultures was
conducted to determine the feasibility of translating/linguisti-
cally validating the instrument in other languages/cultures.
Cognitive Interviews
Semi-structured cognitive and usability testing interviews were
conducted with adolescent and adult participants with asthma to
evaluate the relevance and participant understanding of draft
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completion using the ePRO device.
Recruitment
A second (independent) sample of 65 participants was recruited
in accordance with the aforementioned eligibility criteria used
during the concept elicitation interviews. As previously men-
tioned, quotas were used to ensure that a diverse and represen-
tative sample of participants was recruited.
Interview procedure
Interviews were conducted in three separate successive rounds to
allow for modiﬁcations to the ADSD and subsequent testing among
participants. During the ﬁrst round of interviews (n ¼ 20), partic-
ipants completed a paper version of the ADSD, whereas partic-
ipants in rounds 2 (n ¼ 20) and 3 (n ¼ 25) completed an electronic
version of the diary using a handheld ePRO device (HTC H2
smartphone [HTC Corporation, New Taipei City, Taiwan]). For all
interviews, a semi-structured interview guide was used to guide
the conducting of the interview and to ensure that all areas of the
ADSD were discussed. Speciﬁcally, the ﬁrst part of the interview
involved a brief open-ended exploration of the participants’ expe-
rience of asthma (i.e., concept elicitation). Subsequently, partici-
pants completed the morning or evening version of the ADSD
(depending on the time of day of the interview: before midday or
after midday) as part of a “think aloud” process in which partic-
ipants were asked to speak their thoughts aloud as they read the
instructions and completed the questions on the ADSD. After
completion of this think aloud exercise, participants took part in
both top-level and in-depth cognitive interviews centered on their
experience of completing the ADSD and the relevance and under-
standing of the diary items, instructions, and response options.
Usability of the ePRO device (i.e., whether respondents could use
the electronic device and software appropriately) was also explored
in rounds 2 and 3. All interviews were audio-recorded and tran-
scribed verbatim for the purposes of qualitative analysis.
Analysis
Qualitative analysis of interview transcripts was conducted in
accordance with the qualitative analysis plan and focused specif-
ically on whether the content of the newly developed draft
symptom diary was relevant, appropriate, understood, and inter-
preted consistently by participants.Results
Review of Existing Peer-Reviewed Literature
Searches returned a combined total of 244 abstracts. Only 45
abstracts met the pre-speciﬁed criteria for inclusion; neverthe-
less, after full-text review, 27 more articles were omitted because
they did not contain content relevant to this review as was
expected from their abstracts. Therefore, a ﬁnal total of 18 articles
were included in the review [22–39].
The 18 identiﬁed articles reported qualitative research studies
conducted worldwide with an ethnically and racially diverse
sample of adults and/or adolescents with asthma (Table 1).
Only two articles reported ﬁndings from adolescents aged 11
to 18 years [25,39]; six of the articles, however, reported results
from mixed samples of children and adolescents aged between 6
and 18 years [23,27,28,30,35,37]. Comparable qualitative method-
ologies were used, including semi-structured interviews
[23,28,30–34,36,37], focus groups [22,24–27,35], or a combination
of both [29,38].Core asthma symptoms reported in the literature fell into
three categories: breathing symptoms (e.g., difﬁculty breathing,
shortness of breath, and wheezing), chest symptoms (e.g., chest
tightness, chest pressure, and chest pain), and cough symptoms
(sometimes including the presence of mucus/phlegm). A range of
additional (co-occurring but not disease-deﬁning) symptoms
were identiﬁed. Symptoms were identiﬁed as occurring during
the day or at night, with the impact of such symptoms mediated
by factors such as symptom frequency, duration, and severity/
intensity. In addition, asthma was reported to have impacts on
patients’ physical functioning, emotional/psychological well-
being, sleep, social life/relationships, education, and work. Based
on these ﬁndings, a preliminary conceptual model of the
patients’ experience of asthma was developed, which was sub-
sequently validated using ﬁndings from concept elicitation inter-
views described herein (Fig. 2).
Concept Elicitation Interviews
Participants’ socio-demographic and clinical characteristics
A total of 55 adolescents (n ¼ 25) and adults (n ¼ 30) with asthma
were recruited for participation. Pre-speciﬁed recruitment quotas
were met, as reﬂected in the diverse socio-demographic and
clinical characteristics of the sample (Table 2).
Identiﬁcation of symptom concepts
During the course of the interviews, a total of 70 distinct
symptoms were spontaneously elicited by participants. Of these
70 symptoms, 8 symptoms emerged as the “core” symptoms of
asthma on the basis of the frequency at which they were
spontaneously reported by study participants (Table 3). Consis-
tent with the ﬁndings of the qualitative literature review, these
core symptoms included breathing symptoms (i.e., difﬁculty
breathing, shortness of breath, and wheezing), chest symptoms
(i.e., chest tightness, pressure/weight on chest, and chest pain),
and cough symptoms (i.e., cough and presence of mucus and
phlegm). Of the 62 “non-core” symptoms, the most frequently
mentioned were those that were more commonly associated
with allergies (e.g., sneezing [n ¼ 14] and stuffy nose/nasal
congestion [n ¼ 9]), were non-speciﬁc (e.g., tiredness [n ¼ 14]
and headache [n ¼ 7]), or were known adverse effects of existing
asthma medications (e.g., throat discomfort [n ¼ 15] and sore
throat [n ¼ 9]). Consensus among the expert panel, supported by
the literature review ﬁndings, conﬁrmed that none of these
symptoms should be considered as core symptoms of asthma.
Subgroup analyses according to age quotas, sex, asthma
control, recent exacerbation, and the Expert Panel Report 3
medication steps conﬁrmed the elicitation of the eight core
symptoms of asthma across all subgroups, with no symptom
found to be speciﬁc to or not to occur in a single subgroup.
Although variations in the timing, severity, and duration of
symptoms were observed, conceptual deﬁnitions were remark-
ably consistent. In particular, terms used by adults and adoles-
cents to refer to their symptoms were similar.
In the total study sample, 63 of 70 (90.0%) individual symp-
toms were elicited within the ﬁrst two sets of interviews (n ¼ 37
of 55 participants). Only seven symptoms were mentioned by
participants for the ﬁrst time in the ﬁnal set of interviews (these,
however, were judged to be primarily related to allergic rhinitis
and hay fever): itchy eyes (n ¼ 3), allergies (n ¼ 2), itchy nose (n ¼
2), loss of voice (n ¼ 2), nasal congestion/stuffy nose (n ¼ 2),
watery eyes (n ¼ 1), and swelling of eyes (n ¼ 1). Therefore,
ﬁndings suggest that conceptual saturation was achieved. Fur-
thermore, conceptual saturation was demonstrated for the eight
core symptoms across all the 21 groups deﬁned according to
sub-quotas for age, sex, ethnicity, race, education, asthma con-
trol, history of recent exacerbations, and steps of medication.
Table 1 – Qualitative literature review—overview of study samples and socio-demographic characteristics.
Reference Sample size Study
country
Participant group Age (y) Sex Race/ethnicity/nationality Interviews/
focus groups
Ayala et al.
[25]
n ¼ 50 USA Adolescents 12–17 (n ¼ 50) Male (n ¼ 22)
Female (n ¼ 28)
White (n ¼ 24); African
American (n ¼ 20); others
(not speciﬁed) (n ¼ 6)
Focus groups
Baptist et al.
[22]
n ¼ 46 USA Adults 418 (n ¼ 46) Not speciﬁed White (n ¼ 23); African
American (n ¼ 20); others
(not speciﬁed) (n ¼ 3)
Focus groups
Callery et al.
[28]
n ¼ 25 UK Children and their parents 9–11 (n ¼ 12) Male (n ¼ 16) Not speciﬁed Interviews
Adolescents and their parents 12–16 (n ¼ 13) Female (n ¼ 9)
Chiang [37] n ¼ 11 China Children and their parents 6–12 (n ¼ 11) Male (n ¼ 6) Not speciﬁed Interviews
Adolescents and their parents Female (n ¼ 5)
Edgecombe
et al. [39]
n ¼ 22 UK Children 11–18 Male (n ¼ 16) Not speciﬁed Interviews
Adolescents Female (n ¼ 6)
Gabe et al.
[30]
n ¼ 55 UK Children 11–16 Male (n ¼ 28) White* Interviews
Adolescents Female (n ¼ 27)
Hussein and
Partridge
[29]
n ¼ 60 UK Adolescents 16–50 Not speciﬁed Pakistani* Interviews
Adults Indian* Focus groups
Ostergaard
[33]
n ¼ 20 Denmark Parents of children and adolescents 2–15 Not speciﬁed Not speciﬁed Interviews
Pradel et al.
[23]
n ¼ 32 USA Children 7 (n ¼ 19) Male (n ¼ 20) White (n ¼ 16) Interviews
African American (n ¼ 15)Adolescents 12 (n ¼ 13) Female (n ¼ 12)
Native American (n ¼ 1)
Protudjer
et al. [32]
n ¼ 22 Canada Children 11 Male (n ¼ 11) Not speciﬁed Interviews
Female (n ¼ 11)
Rudell et al.
[38]
n ¼ 55 UK, France,
Germany,
USA
Adolescents 18–90 Male (n ¼ 20) Not speciﬁed Focus groups
Adults Female (n ¼ 35)
Trollvik et al.
[34]
n ¼ 15 Norway Children 7–10 Male (n ¼ 9) Not speciﬁed Interviews
Female (n ¼ 6)
Tumiel-
Berhalter
and Zayas
[24]
n ¼ 22 USA Adults (reporting about their asthma
or proxy reports about their child’s
asthma)
418 Not speciﬁed Not speciﬁed Focus groups
Turner-
Bowker
et al.[26]
n ¼ 21 USA Adults 25–59 Male (n ¼ 8) White (n ¼ 16) Focus groups
African American (n ¼ 4)Female (n ¼ 13)
Asian (n ¼ 1)
Van Dellen
et al. [35]
n ¼ 40 (children
and 28 of their
mothers)
Netherlands Children 7–17 Male (n ¼ 27) Dutch* Focus groups
Adolescents Female (n ¼ 13) Moroccan*
Turkish*
Surinamese*
van den
Bemt et al.
[36]
n ¼ 25 Netherlands Children 6–11 Male (n ¼ 16) Not speciﬁed Focus groups
Female (n ¼ 9)
Vincent et al.
[31]
n ¼ 25 Australia Adults 22–75 Male (n ¼ 11) Not speciﬁed Interviews
Female (n ¼ 14)
Walsh et al.
[27]
n ¼ 40 USA Children 8–17 Not speciﬁed White (non-Hispanic)* Focus groups
Adolescents African American*
Hispanic*
* Sample proportion not speciﬁed.
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Fig. 2 – Conceptual model of asthma symptom experience in adults and adolescents. (Color version of ﬁgure available online).
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Given the aforementioned consistency in ﬁndings across partic-
ipants, it was decided to operationalize the assessment of the
eight core symptoms of asthma via a single diary suitable for use
in adults and adolescents aged 12 years or older. A daily diary
format was chosen to minimize the impact of recall bias and to
account for the day-to-day variation in asthma symptoms. This
format also facilitated both the calculation of symptom-free days
and the assessment of changes in symptom severity over time.
Informed by ﬁndings from the literature review, concept
elicitation interviews, input from the expert panel, and ﬁndings
of the ePRO implementation assessment and translatability
assessment, it was decided that1. patient experience of symptoms should be evaluated in terms
of severity (not frequency or bothersomeness). In particular,
use of a daily diary format was considered to negate the need
to assess symptom frequency and there is evidence of a lack
of conceptual equivalence of “bother” or “bothersomeness”
across cultures and languages [40].2. respondents should be asked to rate each individual symptom
at its “worst” because this is consistent with the FDA PRO
Guidance [13] and most representative of the burden experi-
enced by respondents [41].3. each symptom would be rated using a 0 to 10 numeric rating
scale (NRS) ranging from “not at all” to “as bad as you canimagine.” Numeric ratings on a 0 to 10 scale were used
spontaneously by participants during the concept elicitation
interviews and have the advantage of offering greater grada-
tion of response options (promoting responsiveness/sensitiv-
ity to change). It was also noted that NRS scales can be
universally applied cross-culturally and across languages.4. the diary should be completed twice daily because of the
variability in symptom occurrence (daytime vs. nighttime)
reported by participants. Twice-daily completion would pro-
mote accuracy in reporting and also minimize any potential
recall bias: in the morning (on waking) to best capture
respondents’ experience of symptoms at night when typically
asleep and in the evening (before going to bed) to best capture
the experience of symptoms throughout the daytime when
people typically carry out their usual activities.5. bolding, underlining, capitalization, or use of italics to place
emphasis on certain terms should be avoided because of
problems in applying similar formatting consistently across
all electronic platforms and in all alternate languages.
A single item was generated for seven of the eight core
symptoms. Two items were generated for mucus/phlegm (i.e.,
feeling of mucus/phlegm in the chest and coughing up mucus/
phlegm). Furthermore, although not part of the “core” ADSD, four
additional items assessing important attributes of asthma control
were developed: nighttime awakenings, number of “times” the
Table 2 – Participants’ socio-demographic and clinical characteristics for concept elicitation and cognitive interviews.
Sample demographic and clinical data Concept elicitation interviews Cognitive interviews
12–14 y
(n ¼ 12)
15–17 y
(n ¼ 13)
18–45 y
(n ¼ 16)
≥46 y
(n ¼ 14)
Total
(n ¼ 55)
12–14 y
(n ¼ 18)
15–17 y
(n ¼ 17)
18–45 y
(n ¼ 15)
≥46 y
(n ¼ 15)
Total
(n ¼ 65)
Age, n (y)
Mean 13 16 34 57 31 13 16 32 57 28
Min., Max. 12, 14 15, 17 18, 45 46, 76 12, 76 12, 14 15, 17 19, 45 46, 69 12, 69
Sex, n (%)
Male 9 (75) 6 (46) 4 (25) 6 (43) 25 (45) 11 (61) 8 (47) 6 (40) 4 (27) 29 (45)
Female 3 (25) 7 (54) 12 (75) 8 (57) 30 (55) 7 (39) 9 (53) 9 (60) 11 (73) 36 (55)
Ethnicity, n (%)
Hispanic or Latino (of any race) 2 (17) 2 (15) 5 (31) 1 (7) 10 (18) 6 (33) 5 (29) 5 (33) 3 (20) 19 (29)
Non-Hispanic or Latino 10 (83) 11 (85) 11 (69) 13 (93) 45 (82) 12 (67) 12 (71) 10 (67) 12 (80) 46 (71)
Race, n (%)
White 4 (33) 7 (54) 5 (31) 9 (64) 25 (45) 5 (28) 6 (35) 8 (53) 6 (40) 25 (38)
Black/African American 4 (33) 3 (23) 6 (38) 4 (29) 17 (31) 3 (17) 1 (6) 4 (27) 5 (33) 13 (20)
Multi-racial 1 (8) 0 4 (25) 0 5 (9) 4 (22) 5 (29) 2 (13) 1 (7) 12 (18)
Others 3 (25) 3 (23) 1 (6) 1 (7) 8 (15) 6 (33) 5 (29) 1 (7) 3 (20) 15 (23)
Education level (adults aged Z18 y only), n (%) NA NA N ¼ 30 NA NA N ¼ 30
Some high school 5 (31) 4 (29) 9 (30) 3 (20) 7 (47) 10 (33)
College or higher 11 (69) 10 (71) 21 (70) 12 (80) 8 (53) 20 (67)
Asthma control according to patient score on
asthma control test, n (%) [43]
Well-controlled (Z20) 5 (42) 3 (23) 2 (13) 6 (43) 16 (29) 7 (39) 5 (29) 5 (33) 3 (20) 20 (31)
Not well-controlled (16–19) 4 (33) 6 (46) 6 (38) 2 (14) 18 (33) 6 (33) 6 (35) 5 (33) 1 (7) 18 (28)
Very poorly controlled (r15) 3 (25) 4 (31) 8 (50) 6 (43) 21 (38) 5 (28) 6 (35) 5 (33) 11 (73) 27 (42)
Experience of an exacerbation in the 3 wk before
screening according to physician, n (%) [44]
No exacerbation 2 (17) 5 (38) 3 (19) 8 (57) 18 (33) 8 (44) 7 (41) 7 (47) 7 (47) 29 (45)
Moderate exacerbation 6 (50) 8 (62) 10 (63) 4 (29) 28 (51) 6 (33) 4 (24) 7 (47) 6 (40) 23 (35)
Severe exacerbation 4 (33) 0 3 (19) 2 (14) 9 (16) 4 (22) 6 (35) 1 (7) 2 (13) 13 (20)
Medication step, n (%) [9]
Step 1 2 (17) 1 (8) 2 (13) 0 5 (9) 3 (17) 3 (12) 4 (27) 2 (13) 12 (18)
Step 2 2 (17) 3 (23) 0 2 (14) 7 (13) 3 (17) 2 (6) 3 (20) 0 8 (12)
Step 3 6 (50) 4 (31) 3 (19) 3 (21) 16 (29) 7 (39) 10 (59) 5 (33) 4 (27) 26 (40)
Steps 4–5 2 (17) 5 (38) 8 (50) 9 (64) 24 (44) 5 (28) 2 (12) 1 (7) 7 (47) 15 (23)
Step 6 0 0 3 (19) 0 3 (5) 0 0 2 (13) 2 (13) 4 (6)
Max., maximum; Min., minimum; NA, not available.
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Table 3 – Summary of core symptoms to emerge from concept elicitation interviews.
Symptom Frequency of participants reporting
symptom: spontaneous (S) and
probed (P)
Supporting quote (participant ID*)
Breathing symptoms
Difﬁculty breathing S-55 Q: “And tell me what it’s like to have asthma.”
“Well … it interferes, um, with my breathing.”
Q: “How does it interfere with your breathing?”
Total n ¼ 55 (100%)
“Um, I – I have wheezing. I have difﬁculty breathing.” (101-F-65-WC)
Wheezing S-39; P-7 Q: “OK. OK. When –when do you decide to use the machine? When is
– what – what has to be going on to make you decide, oh, better –
better – use the machine?”
Total n ¼ 46 (83.6%)
“When I wake up – I say, ooh, I feel I’m shortness of breath. You
know? Or my husband can hear me wheeze or – like there’s a
wheezle. And he’ll just plug it up – then.” (311-F-45-VPC)
Shortness of breath S-37; P-2 Q: “And then, what would the symptoms be of asthma that you
would experience?”Total n ¼ 39 (70.9%)
“Um, well, it’s just the wheezing, the shortness of breath, um, and
then, I get – my nose, but no, other than that.” (107-F-17-NWC)
Chest symptoms
Chest tightness S-36; P-4 Q: “What would a typical day of asthma symptoms be like for you?”
Total n ¼ 40 (72.7%) “Well, that congestion – that head fog, the feeling like tightness in
my chest like I can’t breathe ….” (102-F-44-NWC)
Chest pain S-29; P-7 Q: “What else happens on a bad day with asthma? What kind of
symptoms might you have on a bad day?”Total n ¼ 36 (65.6%)
“I’ll just have like tightness in my chest. And it’ll – you know, if it
goes on long enough, which is why I carry my inhaler with me, if it
goes on long enough then probably at the end of the day or
something – it’s like when I’m forcing myself to breathe it causes
chest pains.” (304-F-19-VPC)
Pressure/weight on chest S-25 Q: “I see you’re making a ﬁst.”
Total n ¼ 25 (45.5%) “Right. Uh, it – because it – it – I – I can feel it as the heavi – heaviness
starts, um, and – and it’s just a heaviness in, uh, my, I – I guess the
– right at – right at the top of my chest.” (306-F-54-NWC)
Cough symptoms
Cough S-42; P-7 Q: “So what is the cough like?”
“Sometimes it’s a dry cough. And sometimes it’s a real mucousy
cough, but it starts out – it’ll start out dry.” (501-F-55-VPC)Total n ¼ 49 (89.1%)
Mucus/phlegm S-22; P-13 Q: “Tell me more about that.”
Total n ¼ 35 (63.6%) “Well, when I – when I, um – it – like, it’s – it plays a part, like, when
I’m – if I’mwheezing, I’m going to cough and I’ll be trying to cough,
you know, like, mucus out or something, trying to clear it quick.”
(307-M-44-NWC)
* Participant IDs are presented as follows: participant ID number-sex (M ¼ male; F ¼ female)-age (y)-level of asthma control (WC ¼ well-
controlled, NWC ¼ not well-controlled, VPC ¼ very poorly controlled).
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 4 4 0 – 4 5 0 447relief inhaler was used, number of “puffs” on the relief inhaler,
and impact of symptoms on usual activities.
Cognitive Interviews
Participants’ socio-demographic and clinical characteristics
A combined total of 65 participants with asthma participated in
three rounds of cognitive interviews. All predeﬁned quotas
established at the outset of the study were again met, ensuring
representation and diversity in the recruited sample (see Table 2).
Conceptual coverage
Participant-directed, open-ended discussion at the beginning of
the cognitive interviews corroborated the results from the concept
elicitation interviews and conﬁrmed that the items of the ADSD
encompassed all the symptoms considered by participants as
important for understanding their asthma experience. The rele-
vance of ADSD symptom concepts for participants (from highest tolowest) was as follows: difﬁculty breathing (n ¼ 63 [96.9%]), cough
(n ¼ 63 [96.9%]), shortness of breath (n ¼ 62 [95.4%]), wheezing (n ¼
61 [93.8.%]), chest tightness (n ¼ 61 [93.8%]), chest pressure (n ¼ 59
[90.8%]), mucus/phlegm in the chest (n ¼ 57 [87.7%]), and chest
pain (n ¼ 43 [66.1%]). Thirty-ﬁve participants (53.8%) reported being
woken up from their sleep because of their asthma symptoms.
Almost all participants (n ¼ 50 of 54 [92.6%]) reported limitations in
their usual activities when asked speciﬁcally about the impact of
their asthma symptoms. Similarly, almost all participants (n ¼ 63
[96.9%]) reported using a quick relief inhaler in response to
experiencing asthma symptoms.
ADSD understanding and comprehension
Overall, ADSD items and instructions were generally well under-
stood and consistently interpreted across all age groups and
education levels (Table 4). As a result, very few changes were
implemented throughout the three rounds of interviews, with
most of the items and instructions retaining their wording
Table 4 – Summary of feedback during cognitive interviews.
ADSD content Supporting quote (participant ID*)
ADSD items
Item 1. Difﬁculty breathing “Um, to me, it means like you have problems breathing, that like you’re not g – getting like
enough air, and you’re like about to like pass out.” (411-F-12-VPC)
Item 2. Wheezing† “It’s kind of a like raspy, it’s hard to describe … it kind of sounds like an insect’s buzz. It kind of
sounds like that, and it’s really difﬁcult to inhale.” (302-M-15-WC)
Item 3. Shortness of breath “Just like you can’t catch your breath. Like it feels like you just like ran a mile.” (410-M-19-NWC)
Item 4. Pressure/weight on chest “Feels like somebody’s – something is sitting on my chest with a lot of weight.” (106-F-60-WC)
Item 5. Chest tightness “Um, tightness as far as like your lungs not being able to expand.” (209-M-48-VPC)
Item 6. Chest pain “I guess a sharpness – a sharp sensation in, uh – in your lungs.” (102-M-49-NWC)
Item 7. Cough “I do cough a lot – and it does affect me. And it can sometimes like bother me right here because
I’m coughing so much (pointing to throat).” (111-M-13-NWC)
Item 8. Mucus/phlegm “Uh, that means to me that there’s substances in my lungs, like mucus and stuff.” (108-M-15-
NWC)
Item A (M). Nighttime awakenings “Out of all my asthma symptoms, in the middle of the night did I ever wake up because of one of
them?” (109-M-13-NWC)
Item A (E). Impact on daily activities “It’s asking me how – how much has my asthma interfered with me getting things done.” (110-F-
33-NWC)
Item B1. Times used quick relief inhaler “It’s like how many times did – did I need to take my inhaler?” (207-F-24-NWC)
Item B2. Puffs of quick relief inhaler “It’s how many times I pressed down on the inhaler.” (108-M-15-NWC)
“Puffs is every time you inhale and exhale.” (306-F-50-VPC)
General features of the ADSD
Recall period “I rated how I felt before I went to bed last night. So around before I went to bed I – and took a
snapshot in time in my brain, OK, how did I feel at that time?” (401-F-39-WC)
“I was thinking about just the time I’d gotten out of bed to now.” (104-F-14-WC)
Response continuum “Oh, it’s a pretty good scale, I guess, um. Makes sense. Uh, I could rate it from zero to 10 pretty
easily.” (318-M-15-NWC)
ePRO usability (rounds 2 and 3 only) “It was very, very easy. It felt like the operating system worked really well.” (414-M-29-VPC)
“It made it easy for me, because I use a smartphone. So I use applications like this all the time,
and they’re pretty much the similar size.” (110-F-33-NWC)
ADSD, asthma daily symptom diary; ePRO, electronic patient-reported outcome.
* Participant IDs are presented as follows: participant ID number-sex (M ¼ male; F ¼ female)-age (y)-level of asthma control (WC ¼ well-
controlled, NWC ¼ not well-controlled, VPC ¼ very poorly controlled).
† Wheezing as assessed on the ADSD is inclusive of both the sensation and the associated sound of wheezing. Wheezing is measured using a
single item and does not represent an item assessing multiple concepts (e.g., double enquiry).
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participant feedback, these were only minor.
On the basis of the results from the three rounds of inter-
views, it was agreed that no further symptoms needed to be
added to the draft ADSD. Nevertheless, on the basis of the results
of the ﬁrst two rounds of interviews, the Asthma WG agreed that
the item assessing coughing up mucus/phlegm should be
removed before the testing in round 3. This was primarily
because of conceptual overlap and redundancy with items
assessing cough and the feeling of mucus/phlegm in the chest
that had led to some confusion among a small number of
participants. Findings from round 3 conﬁrmed that the remaining
items were well understood and interpreted consistently by
participants.
When asked about completing the diary twice a day, most
participants (n ¼ 57 [87.7%]) stated that it was important to assess
their asthma symptoms twice a day because of the variability in
their experience of symptoms during the day and at nighttime.
When understanding of the speciﬁed recall periods was explored,
almost all participants (n ¼ 61 [93.8%]) provided feedback con-
sistent with understanding of the recall period instructions.
Response options for ADSD appeared to be well understood
and consistently interpreted by participants. Most participants
who were asked (n ¼ 57 of 63 [90.4%]) found the NRS easy to
complete and preferable to having verbal response options.Consideration of participant responses to the morning and
evening diary during the interviews revealed endorsement of
options for individual items across the entire response contin-
uum (from 0 to 10).
Participant feedback supported the ease of completing the
ADSD on the ePRO device, and no issues with presentation,
selection of responses, or navigating through the instrument
were identiﬁed. Furthermore, no differences in participant under-
standing and the response options selected by participants were
observed depending on whether the ADSD was completed in
portrait or landscape orientation.
After the completion of the three rounds of cognitive inter-
views, a meeting was convened between the Asthma WG and the
expert panel. Findings from the cognitive interviews were dis-
cussed and there was agreement to retain the items assessing the
eight core symptoms of asthma (as tested in round 3 of the
cognitive interviews) for testing in the planned quantitative pilot
study. On the basis of the feedback from the expert panel, an
optional item that could be used to assess nebulizer use in
clinical trials (as per sponsor requirements) was developed. This
item was developed using language parallel to items assessing
relief inhaler use and tested in the cognitive interviews. The
hypothesized ADSD conceptual framework is presented in
Figure 3 and will be ﬁnalized after the completion of a planned
quantitative study to explore content validity.
Fig. 3 – Hypothesized ADSD conceptual framework (this is to be ﬁnalized after the completion of the quantitative study to
explore content validity). ADSD, asthma daily symptom diary. (Color version of ﬁgure available online).
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The ADSD has been developed by a multidisciplinary team
(involving representatives from 13 pharmaceutical ﬁrms, the C-
Path PRO Consortium, PRO consultants, and expert panelists) in
close accordance with the best available standards for PRO
development outlined in the FDA PRO Guidance [13]. Importantly,
extensive involvement of a demographically and clinically
diverse sample of adults and adolescents with asthma via
qualitative research (in the generation and evaluation of content
of the ADSD) has been comprehensively documented.
Research supporting the development of the ADSD highlights
a consistency in the way in which adults and adolescents with
asthma talk about their symptoms (regardless of demographic or
clinical differences). This is reﬂected in the eight core symptoms
of asthma that are assessed as part of the ADSD. The ADSD seeks
to ameliorate issues with existing instruments assessing asthma
symptom severity in terms of inadequate or incomplete concep-
tual coverage (no existing PRO instruments assess all eight
symptoms), use of recall periods that require participants to
average over time or think back to an earlier state, inclusion of
single items measuring multiple concepts, and use of response
options that may limit ability to distinguish between asthma
states and to demonstrate change in symptoms over time [42].
The authors acknowledge the publication of a recent asthma
symptom diary by Globe et al. [43] after the completion but before
the publication of this research, which goes some way in
addressing some of the aforementioned limitations of existing
instruments [43]. Nonetheless, there are key differences between
the ADSD and this aforementioned instrument: the ADSD
assesses eight rather than four asthma symptoms and assesses
asthma severity using a 0 to 10 NRS as opposed to a ﬁve-point
verbal rating scale. It should also be noted that content gener-
ation and validation of the ADSD has paid careful attention in
ensuring relevance and comprehension among diverse groups of
patients varying according to socio-demographic (e.g., age, sex,
race, ethnicity, and education level) and clinical (e.g., asthma
severity and medication) characteristics, which have to date been
largely ignored.
Content validity is typically established by evidence from
qualitative studies that the content of the PRO instrument (items,instructions, response options, etc.) adequately reﬂects the
intended measurement concepts. The PRO instrument should
reﬂect the way in which the target population understand and
discuss these concepts [13,44]. It is important to establish content
validity before other measurement properties are evaluated
because evidence of other types of validity (e.g., construct
validity) or reliability (e.g., reproducibility of scores) will not
overcome problems with content validity [13]. As the next step
in the development of the ADSD, a pilot quantitative study is
planned to generate further evidence to support the content
validity of the instrument and to provide initial insights into
item performance, reliability, and construct validity. Future plans
include examining the ADSD’s psychometric properties, includ-
ing its ability to detect meaningful change in asthma symptom
severity, using data collected in longitudinal treatment trials.Conclusions
The ADSD was developed to facilitate comprehensive and reliable
assessment of asthma symptoms from a patient’s perspective.
Evidence from extensive qualitative research provides support for
the content validity of the instrument in adults and adolescents.
Future research will seek to generate quantitative data to provide
further evidence of content validity and insights into the reli-
ability and psychometric validity of the ADSD.Acknowledgments
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